載入中
NASDAQHealthcareDrug Manufacturers - Specialty & Generic
最新資料
US$40.26
−US$0.35 · -0.86%
Alkermes plc, a biopharmaceutical company, engages in the research, development, and commercialization of pharmaceutical products to address unmet medical needs of patients in therapeutic areas in the United States, Ireland, and internationally. The company has a portfolio of proprietary commercial products for the treatment of opioid dependence, alcohol dependence, schizophrenia, bipolar I, and a pipeline of clinical and preclinical product candidates in development for neurological disorders. Its marketed products include ARISTADA, an intramuscular injectable suspension for the treatment of schizophrenia; ARISTADA INITIO for the treatment of schizophrenia in adults; VIVITROL for the treatment of alcohol and prevention of opioid dependence; LYBALVI, an oral atypical antipsychotic drug candidate for the treatment of adults with schizophrenia and bipolar I disorder; and LUMRYZ, an extended-release oral suspension product for the treatment of cataplexy or EDS in pediatric patients. The company also offers proprietary technology platforms to third parties to enable them to develop, commercialize, and manufacture products. It has collaboration agreements primarily with Janssen Pharmaceutica N.V., Janssen Pharmaceutica Inc, and Janssen Pharmaceutica International. Alkermes plc was founded in 1987 and is headquartered in Dublin, Ireland.
收盤時
US$40.26
−US$0.35 · -0.86%
盤後
US$40.26
US$0.00 · 0.00%
10月12日 下午7:30 ET
盤中時間採用ET。市場資料可能有所延遲。
Alkermes plc, a biopharmaceutical company, engages in the research, development, and commercialization of pharmaceutical products to address unmet medical needs of patients in therapeutic areas in the United States, Ireland, and internationally. The company has a portfolio of proprietary commercial products for the treatment of opioid dependence, alcohol dependence, schizophrenia, bipolar I, and a pipeline of clinical and preclinical product candidates in development for neurological disorders. Its marketed products include ARISTADA, an intramuscular injectable suspension for the treatment of schizophrenia; ARISTADA INITIO for the treatment of schizophrenia in adults; VIVITROL for the treatment of alcohol and prevention of opioid dependence; LYBALVI, an oral atypical antipsychotic drug candidate for the treatment of adults with schizophrenia and bipolar I disorder; and LUMRYZ, an extended-release oral suspension product for the treatment of cataplexy or EDS in pediatric patients. The company also offers proprietary technology platforms to third parties to enable them to develop, commercialize, and manufacture products. It has collaboration agreements primarily with Janssen Pharmaceutica N.V., Janssen Pharmaceutica Inc, and Janssen Pharmaceutica International. Alkermes plc was founded in 1987 and is headquartered in Dublin, Ireland.
日內區間
目前US$40.26
52週區間
目前US$40.26
盤中時間採用ET。市場資料可能有所延遲。
Alkermes plc, a biopharmaceutical company, engages in the research, development, and commercialization of pharmaceutical products to address unmet medical needs of patients in therapeutic areas in the United States, Ireland, and internationally. The company has a portfolio of proprietary commercial products for the treatment of opioid dependence, alcohol dependence, schizophrenia, bipolar I, and a pipeline of clinical and preclinical product candidates in development for neurological disorders. Its marketed products include ARISTADA, an intramuscular injectable suspension for the treatment of schizophrenia; ARISTADA INITIO for the treatment of schizophrenia in adults; VIVITROL for the treatment of alcohol and prevention of opioid dependence; LYBALVI, an oral atypical antipsychotic drug candidate for the treatment of adults with schizophrenia and bipolar I disorder; and LUMRYZ, an extended-release oral suspension product for the treatment of cataplexy or EDS in pediatric patients. The company also offers proprietary technology platforms to third parties to enable them to develop, commercialize, and manufacture products. It has collaboration agreements primarily with Janssen Pharmaceutica N.V., Janssen Pharmaceutica Inc, and Janssen Pharmaceutica International. Alkermes plc was founded in 1987 and is headquartered in Dublin, Ireland.
日內區間
目前US$40.26
52週區間
目前US$40.26
獲利能力占已公布營收的百分比。
營收
營業利益
淨利
| 項目（USD） | 2025會計年度 | 2024會計年度 | 2023會計年度 | 2022會計年度 | 2021會計年度 |
|---|---|---|---|---|---|
| 營收 | 14.76億 USD | 15.58億 USD | 16.63億 USD | 11.12億 USD | 11.74億 USD |
| 銷貨成本 | 1.96億 USD | 2.45億 USD | 2.53億 USD | 2.18億 USD | 1.97億 USD |
| 毛利 | 12.79億 USD | 13.12億 USD | 14.1億 USD | 8.94億 USD | 9.76億 USD |
| 研究與開發 | 3.24億 USD | 2.45億 USD | 2.71億 USD | 2.73億 USD | 2.91億 USD |
| 銷售、一般及管理費用 | 7.15億 USD | 6.45億 USD | 6.9億 USD | 5.91億 USD | 5.5億 USD |
| 營業費用 | 10.25億 USD | 8.92億 USD | 9.96億 USD | 9億 USD | 8.79億 USD |
| 利息收入 | 4530.4萬 USD | 4245萬 USD | 3085.4萬 USD | 762.9萬 USD | 240.8萬 USD |
| 利息支出 | 1227.7萬 USD | 2257.8萬 USD | 2303.2萬 USD | 1304萬 USD | 1121.9萬 USD |
| 折舊和攤銷 | 2716.5萬 USD | 2853.3萬 USD | 7492.7萬 USD | 7786.2萬 USD | 7865.2萬 USD |
| 營業利益 | 2.54億 USD | 4.21億 USD | 4.14億 USD | −608.9萬 USD | 9774.6萬 USD |
| 淨利 | 2.42億 USD | 3.67億 USD | 3.56億 USD | −1.58億 USD | −4816.9萬 USD |
公司資料更新於 2026年10月13日。
近期已公布業績
近期已公布業績
第三方分析師預期可能變動，並非 GoAI 建議。
報告持有此股票曝險的交易所交易基金。
Vanguard Morningstar Total Stock Market ETFVTI2.49億0.01%2.3兆 USD0.03%US$381.57-0.10%
Vanguard Morningstar Small-Cap ETFVB1.8億0.10%1853億 USD0.03%US$288.16-0.46%
iShares Russell 2000 ETFIWM1.78億0.23%787.4億 USD0.19%US$277.9-0.37%
State Street SPDR S&P Biotech ETFXBI1.3億1.32%103.03億 USD0.35%US$151.4-1.54%
Vanguard Morningstar Small-Cap Growth ETFVBK1.03億0.23%447億 USD0.05%US$340.88-1.12%
Vanguard Extended Market ETFVXF9100.43萬0.09%954億 USD0.05%US$233.52-0.63%
First Trust NYSE Arca Biotechnology Index FundFBT7078.71萬2.45%28.91億 USD0.55%US$263.9-0.57%
State Street SPDR Portfolio S&P 600 Small Cap ETFSPSM6245.83萬0.39%158.4億 USD0.03%US$53.42-0.06%Vanguard Morningstar Total Stock Market ETFVTIVanguard Morningstar Small-Cap ETFVBiShares Russell 2000 ETFIWMState Street SPDR S&P Biotech ETFXBIVanguard Morningstar Small-Cap Growth ETFVBKVanguard Extended Market ETFVXFFirst Trust NYSE Arca Biotechnology Index FundFBTState Street SPDR Portfolio S&P 600 Small Cap ETFSPSMAI 生成內容及延遲市場資料僅供資訊與教育用途，不構成投資建議。
